Drugs and insomnia
Insomnia occurs in so many circumstances that it is often difficult to know when a hypnotic should be used and which is most suitable. In the past 10 years or so considerable advances have been made, however, in understanding sleep and sleep disturbance, and many more drugs, both diazepines and non-diazepines, have been developed to promote sleep. Late last year the National Institutes of Health, Bethesda, held a consensus development conference on "Drugs and insomnia: the use of medications to promote sleep." A much clearer view of the use of hypnotics evolved, and the National Institutes of Health is to be congratulated for providing the opportunity to make this possible.
Consensus conferences are little known outside the United States, but they provide a useful way of updating knowledge. On this occasion after a day and a half of invited presentations a panel of psychiatrists, pharmacologists, epidemiologists, general practitioners, and representatives of the public prepared a statement which dealt with the circumstances in which hypnotics should be used, the pharmacological properties which should be considered, and the principal cautions and risks associated with prescribing these drugs.
Insomnia is a symptom of various conditions and indicates the need for systematic assessment of the medical, psychiatric, and other causes. Analysis of insomnia is best done under three headings-transient, short term, and long term (chronic).
Transient insomnia occurs in those who normally sleep well and is usually due to an alteration in the conditions which surround sleep (for example, noise) or to an unusual pattern of rest, as in shiftwork or intercontinental travel. A hypnotic may or may not be needed, depending on whether the patient reacts unfavourably to unfamiliar surroundings, but when treatment is given a rapidly eliminated hypnotic is appropriate, and it should be needed on only a couple of occasions.
Short term insomnia is usually related to an emotional problem or to a serious medical illness. It may last for a few weeks and may recur. Good management is needed to avoid long term problems, and proper attention to sleep hygiene is essential. A hypnotic is likely to be useful, but it should be given for not more than three weeks-preferably for only a week or so. Intermittent use is desirable, with skipping of some nightly doses after the first few nights of good sleep. A rapidly eliminated drug is usually appropriate to avoid impaired daytime alertness, though for those with any substantial anxiety a slowly eliminated drug may be preferredbut care must be taken to avoid undue sedation related to the accumulation of the drug.
There was considerable controversy over the use of hypnotics in chronic insomnia. Careful diagnosis is essential before a decision is made. Possibly one third to one half of all such patients have an underlying psychiatric disorder, especially depression, and these patients may need specific treatment. Another group includes those with chronic abuse of drugs or alcohol, and yet others may have specific sleep disorders. From a practical point of view the most important, particularly in the elderly, is sleep apnoea, and in such patients -mainly obese men with a history of snoring or daytime sleepiness or both-sedatives are currently considered to be contraindicated. Nevertheless, in many patients with chronic insomnia no apparent cause can be established. In these the combined approach of improved sleep hygiene and drug treatment will be needed. The essentials are exercise, controlled curtailment of sleep, and reduction in stress, together with restriction of caffeine and alcohol and the intermittent use of a hypnotic for one night in three for up to a month. In these patients the longer acting benzodiazepines may be more appropriate. If after about a month such treatment is unsuccessful a trial of a sedative antidepressant for, say, a further four weeks was recommended-even in the abser -e of clear cut evidence of depression. This approach needs careful consideration, however, and at the moment may not be widely accepted.
The diazepines are to be preferred to the barbiturates not only because of their safety but also because of their therapeutic usefulness. The main problems which may arise from their use are residual daytime effects (which may be avoided by appropriate dosage of rapidly eliminated compounds); rebound insomnia on withdrawal (which may be avoided by using appropriate doses for short periods and a gradual reduction of dose at the end of the treatment period); dependence (which may be minimised by low intermittent dosage, short duration of administration, and gradual withdrawal if continuous treatment has been given for more than a month); and potentiation by other sedative substances. To avoid these the panel emphasised that patients should always receive the smallest possible dose for the shortest clinically necessary time and that the physician should educate patients in the desirability of the occasional use of low doses and monitor their progress carefully to achieve the desired result.
In all, the recommendations of the panel provide a sensible approach. Treatment 
